

September 17, 2018 • Hall-A Scientific Session - 1

08:00-08:30	Registration
08:30-09:00	Opening Ceremony
09:00-09:45	Rogério Gaspar , <i>University of Lisbon, Portugal</i> Nanomedicine a roadmap: From integrative key enabling technologies to integrative and personalised healthcare
09:45-10:30	Samir Mitragotri , <i>Harvard University, United States</i> Bio-mimetic and bio-inspired designs of nanoparticles
10:30-10:45	Coffee Break
10:45-11:30	Mansoor A. Khan , <i>Texas A&M University, United States</i> Technological advances of nanomedicines: Status update and regulatory considerations
11:30-12:00	Peter Swaan , <i>University of Maryland, United States</i> Uptake and trafficking of nanopharmaceuticals: A particle's journey into and throughout the cell and its compartments
12:00-12:30	Hideyoshi Harashima , <i>Hokkaido University, Japan</i> Multifunctional envelope-type nano device for passive/active targeting as well as controlled intracellular trafficking of nucleic acids for personalized nanomedicine
12:30-14:00	Lunch
14:00-14:30	Elias Fattal , <i>University of Paris-Sud, France</i> Glucocorticoids in nanopharmaceuticals for the treatment of inflammatory diseases
14:30-15:00	Erem Bilensoy , <i>Hacettepe University, Turkey</i> Cholesterol-targeted nanoparticles to overcome drug resistance in anticancer and antibiotics
15:00-15:30	David Brayden , <i>University College Dublin, Ireland</i> Nanoparticle constructs for delivering oral peptides: Data and learnings from the EU FP7 consortium, TRANS-INT
15:30-15:45	Coffee Break
15:45-16:15	Nils Rottmann , <i>BASF SE, Germany</i> Liquid fill of hard gel capsules – an alternative to hot melt extrusion?
16:15-16:45	Daniel Sieber , <i>Ashland, Germany</i> Impact of excipient variability on QbD
16:45-17:15	Engin Bayram , <i>Ant Teknik Cihazlar Ltd., Turkey</i> LC/MS/MS Method package: Cell culture profiling
17:15-17:45	Manish Ghimire , <i>Colorcon, United Kingdom</i> Getting the Medicine down with New Slippery Tablet Coating

September 17, 2018 • Hall-B

Current position of Turkey for the worldwide clinical trials: What is the next step?

13:30-13:45	Hakkı Gürsöz , <i>President-Turkish Medicines and Medical Devices Agency-TMMDA</i> Current view of TMMDA on clinical trials
13:45-14:15	Nihan Burul Bozkurt , <i>Head of Clinical Trials Department-Turkish Medicines and Medical Devices Agency-TMMDA</i> Challenges and opportunities on clinical trials-what is next?
14:15-14:30	Zeliha Koçak Tufan , <i>Council of Higher of Education-CoHE, Turkey</i> Higher education institutions, university hospitals of Turkey and the potential of the clinical trials
14:30-14:45	Emine Firdevs Yıldırım , <i>The Scientific and Technological Research Council of Turkey-TÜBİTAK, Turkey</i> National academic R&D grants in clinical researches
14:45-15:00	Coffee Break
15:00-15:15	Kaan Kavaklı , <i>Ege University, Turkey</i> Phase 1 studies conducted in Turkey, current problems and solutions
15:15-15:30	Aydın Erenmemişoğlu , <i>Farmagen Center for Good Clinical Practice, Turkey</i> Current status and recent improvements of bioequivalence studies in Turkey
15:30-15:45	Serhat Mete Hüsemoğlu , <i>Association of Research Based Pharmaceutical Companies-AİFD, Turkey</i> A general view of clinical trials in Turkey: Where we were and where we are?
15:45-16:00	Coffee Break
16:00-16:15	Betül Erdoğan , <i>Merck Sharp Dohme, Turkey</i> Turkey's current position in global clinical research arena, proposals to fulfill 2023 vision objectives
16:15-16:30	Barış Erdoğan , <i>Clinerion, Turkey</i> The importance of Real World Data (RWD) in clinical and epidemiological research
16:30-16:45	Nurşah Çetinkaya , <i>Association of Clinical Research, Turkey</i> What should we do about clinical research in Turkey today and in the near future?
16:45-17:45	Panel Discussion

*Session presentations will be in Turkish

September 18, 2018 • Hall-A

Scientific Session - 2

08:30-09:00	Seyed Moein Moghimi , <i>Newcastle University Medical School, United Kingdom</i> Modulation of adverse injection reactions to nanomedicines by macrophages and independent of complement activation
09:00-09:30	Thomas J. Webster , <i>Northeastern University, United States</i> Nanotechnology and nanomaterials: Promises for improved tissue regeneration
09:30-10:00	Jean-Christophe Leroux , <i>ETH Zürich, Switzerland</i> Ultrasound-mediated delivery of drug-loaded liposomes for chemotherapy sensitization of glioblastoma
10:00-10:15	Coffee Break
10:15-10:45	Gert Storm , <i>Utrecht University, Netherlands</i> Targeted nanopharmaceuticals: Do they fulfill their promise?
10:45-11:15	Veronique Preat , <i>Université Catholique de Louvain, Belgium</i> Nanoparticle-based drug delivery systems for cancer treatment: A scientific and commercial outlook as the field matures
11:15-11:45	Bruno De Geest , <i>Ghent University, Belgium</i> Engineering the immune system with synthetic biomaterials
11:45-12:15	Yvonne Perrie , <i>University of Strathclyde, United Kingdom</i> Designing liposomal adjuvants for the next generation of vaccines
12:15-13:30	Lunch
Best Ph.D. Thesis Presentations' Presentations	
13:30-13:45	Huriye Demir , <i>Hacettepe University, Turkey</i> Preparation of Rivaroxaban Nanocrystals and In Vitro-In Vivo Assays
13:45-14:00	Gülen Melike Demirbolat , <i>Gazi University, Turkey</i> The Development of Nanoparticles and Quantum Dots Effective for Cancer Therapy
14:00-14:15	Özgür Eşim , <i>University of Health Sciences, Turkey</i> Development of A Nose to Brain Formulation, Evaluation of In Vitro And Rat Animal Model
14:15-14:30	Dilara Örgül , <i>Hacettepe University, Turkey</i> Formulation of Tissue Scaffolds Containing Nanoparticulate Statin and Stem Cells for Diabetic Wound Healing and In Vitro/In Vivo Evaluation
14:30-14:45	Ayben Işılray Özdoğan , <i>Hacettepe University, Turkey</i> Development of a Delivery System for Statin in the Treatment of Periodontal Disease
14:45-15:00	Onur Pınarbaşı , <i>Hacettepe University, Turkey</i> Preparation of Lanthanum Carbonate Formulations, In Vitro Evaluation and Bioactivity Studies
15:00-15:15	Serdar Tort , <i>Gazi University, Turkey</i> In Vitro/In Vivo Evaluation of Nanofiber Wound Dressings Prepared via Electrospinning Method
15:15-15:30	Tahir Emre Yalçın , <i>Gazi University, Turkey</i> Development and Evaluation of Lipid Polymer Hybrid Nanoparticles Drug Delivery Systems
15:30-16:00	Coffee Break
Oral Presentation Session	
16:00-16:07	OP-01-Devrim Demir Dora , <i>Akdeniz University, Turkey</i> Pei-Polyplex Mediated Delivery of Stat3-Shrna PDNA Into Triple-Negative Breast Cancer Cells
16:08-16:15	OP-02-Gülen Melike Demirbolat , <i>Cumhuriyet University, Turkey</i> The Combination of Erlotinib Hydrochloride and Dexketoprofen Trometamol in Chitosan Nanoparticles for the Cancer Treatment: In Vivo Investigation
16:16-16:23	OP-03-Nihan İzat , <i>Hacettepe University, Turkey</i> Influence of Permeability Enhancers on the Paracellular Permeability of Metformin Hydrochloride Across Caco-2 Cells
16:24-16:31	OP-04-Mohammad Karim Haidar , <i>Hacettepe University, Turkey</i> Application of a Novel Polymeric Electrospun Nanocomposite Incorporating Neuroprotective Drugs in Rat Sciatic Nerve Injury Model
16:32-16:39	OP-05-Nazlı Erdoğan , <i>Hacettepe University, Turkey</i> Optimized Novel Aprepitant Loaded Oral Nanoparticles and Nanocapsules for Bioavailability Improvement
16:40-16:47	OP-06-Semih Çalamak , <i>Hacettepe University, Turkey</i> Detection of Prostate Cancer Biomarkers via In-Situ Gold Nanoparticle Growth on LSPR Surfaces
16:48-16:55	OP-07-Selin Seda Timur , <i>Hacettepe University, Turkey</i> Comparison of Two Mucoadhesive Polymers for Local Drug Delivery into Oral Cavity
16:56-17:03	OP-08-Erkan Azizoğlu , <i>Ege University, Turkey</i> Microneedle Fabrication with 3D Printed Parts
17:04-17:11	OP-09-Merve Çelik Tekeli , <i>Gazi University, Turkey</i> In Vitro Lipolysis Test for Exendin-4 And Exendin-4/Chymostatin Loaded Self Nanoemulsifying System
17:15-18:15	Poster Session
20:00-24:00	Gala Dinner

September 18, 2018 • Hall-B

Biotech Products-what is next for the further step?

09:00-09:15	Ali Alkan, Vice President-Turkish Medicines and Medical Devices Agency-TMMDA Current view of TMMDA on biotech products
09:15-09:45	Hacer Coşkun Çetintaş, Head of Department-Turkish Medicines and Medical Devices Agency-TMMDA A comparative review of marketing authorization needs of biosimilars
09:45-10:15	Ali Osman Kılıç, Health Institutes of Turkey-TÜSEB, Turkey Health policies and TÜSEB vision on health biotechnology future
10:15-10:45	Elif İnci Somuncuoğlu, Turkish Medicines and Medical Devices Agency-TMMDA Clinical trials on biosimilar products-Current status from the point of view of TMMDA
10:45-11:00	Coffee Break
11:00-11:30	A. Filiz Öner, Hacettepe University, Turkey Biosimilar and next generation monoclonal antibodies
11:30-12:00	Emirhan Nemutlu, Hacettepe University, Turkey Analytical perspectives on biotech products: A general view from the point of CTD
12:00-12:30	Levent Öner, Hacettepe University, Turkey Pharmacokinetic considerations of biosimilars
12:30-13:00	Sadi Satılmış Özdem, Akdeniz University, Turkey Preclinical evaluation of biotechnological medicinal products
13:00-14:00	Lunch
14:00-14:30	Ramazan Karaduman, Abdi-Bio, Turkey Biosimilars and recent developments
14:30-15:00	Eslam El Berry, Amgen Inc., United States Overcoming pharmacovigilance challenges with biosimilars
15:00-15:30	Patricia Lufburrow, Biomarin, United States QC testing for biologics
15:30-15:45	Coffee Break
15:45-16:15	Aziz Çaylı, Florabio, Turkey First the factory then the product – Platform approach in production of vaccines and biopharmaceuticals
16:15-16:55	Martin Schiestl, Sandoz, Austria EMA regulatory approval criteria of biosimilars and importance of analytical & clinical studies
16:55-17:45	Panel Discussion
20:00-24:00	Gala Dinner

*Session presentations will be in Turkish

September 19, 2018 • Hall-A

Scientific Session - 3

08:30-09:00	Ick Chan Kwon , <i>Korea Institute of Science and Technology, Korea</i> Nanopharmaceuticals as a pros for theragnosis
09:00-09:30	Alexander M. Seifalian , <i>The London BioScience Innovation Centre, United Kingdom</i> Toxicology and clinical potential of nanoparticles
09:30-10:00	Twan Lammers , <i>RWTH Aachen University Clinic, Germany</i> Macro-nanomedicine
10:00-10:15	Coffee Break
10:15-10:45	Ijeoma F. Uchegbu , <i>UCL School of Pharmacy, United Kingdom</i> The nanoparticle and the differentiated medicine
10:45-11:15	Roland Bodmeier , <i>Freie Universität Berlin, Germany</i> Nanocarriers for dermal delivery
11:15-11:45	Joke Bouwstra , <i>University of Leiden, The Netherlands</i> Nanoparticulate delivery of vaccines by hollow and coated microneedles
11:45-12:15	Davide Brambilla , <i>University of Montreal, Canada</i> Design of polymeric microneedles for diagnostic and monitoring applications
12:15-13:30	Lunch
13:30-14:00	Maria Jesus Vicent , <i>Centro de Investigación Principe Felipe, Spain</i> Star-shaped polypeptide conjugates with controlled self-assembly as drug delivery systems
14:00-14:30	Enrico Mastrobattista , <i>Utrecht University, The Netherlands</i> Nucleic acid delivery with synthetic nanoparticles
14:30-15:00	Ho Cheung Shum (Anderson) , <i>The University of Hong Kong, Hong Kong</i> Droplet-based formulations for encapsulation of drugs
15:00-15:30	Wuge Briscoe , <i>University of Bristol, United Kingdom</i> Understanding nanoparticle cellular entry: A physicochemical perspective
15:30-16:00	Closing Ceremony